Podcasts about tumors

Recorded by Kaveh Akbar for Poem-a-Day, a series produced by the Academy of American Poets. Published on June 16, 2025. ⁠⁠⁠⁠⁠⁠www.poets.org

»Metoda je zelo prijazna pacientom in lahko si predstavljate, kako z njo od znotraj obsevamo tumorsko tkivo.«Radioembolizacija je posebna in učinkovita metoda za odstranjevanje rakavega tkiva. Prim. prof. dr. Martin-Michael Uggowitzer vodi Inštitut za radiologijo in nuklearno medicino v Deželni bolnišnici LKH Leoben na avstrijskem Štajerskem. Pravi, da so lani s postopkom radioembolizacije zdravili 15 bolnic in bolnikov s turskimi tvorbami v jetrih. Pričakuje, da bo letos ta številka še višja. Tovrstno terapijo v Avstriji ob Leobnu izvajajo še trije ali štirje medicinski centri, v Sloveniji pa ljubljanski Klinični center. Tako kot v Avstriji stroške radioembolizacije tudi v Sloveniji krije zdravstvena zavarovalnica. Podrobneje v Ultrazvoku.

What do you do when cancer is always present in your family? David Mauk lost his mother, his sister, and other loved ones to breast cancer. He knows what it's like to grow up surrounded by the reality of cancer and to carry the BRCA gene. In today’s episode, you’ll hear: How genetic testing changed the choices his family made What it feels like to be a cancer advocate in Washington, D.C. Why sharing your family history can help save lives Support The Rose HERE. Subscribe to Let’s Talk About Your Breasts on Apple Podcasts, Spotify, iHeart, and wherever you get your podcasts. Key Questions Answered What impact did breast cancer have on David Mauk's family? What is the significance of the BRCA gene in David’s family? How did David’s family talk about breast cancer while he was growing up? How did David cope with losing his mother at such a young age? Did David himself undergo genetic testing and what were the results? How does David’s family approach genetic testing and health surveillance today? What has David done as an advocate for cancer research and awareness? Why does David believe early detection and knowing your family history is so crucial? What advice does David have for those with a family history of cancer? How has cancer research and treatment changed since previous generations? Timestamped Overview 00:00 Family, Cancer, Advocacy, Gene Awareness 04:31 Air Force Headsets Linked to Tumors 07:36 "Air Force Brat’s Journey" 11:07 Cancer Society Fundraising Champions 14:11 "Make Cancer Conversations Personal" 15:41 "Missing Maternal Memories" 22:00 Family Migration Journey 22:57 Living Positively Amidst Fear 25:57 Discovering Family Through DNA Insights 29:37 Empowering Young Women Against Breast CancerSee omnystudio.com/listener for privacy information.

Cancer-fighting implant shows promise in treating melanoma, pancreatic and colorectal tumors. Rice-led study serves as foundation for FDA investigational new drug application and emerging new company to launch from RBL LLC. Veiseh's team at Rice University has created an implant that functions like a “cytokine factory,” delivering IL-12 — a powerful immune-stimulating molecule — directly into the tumor environment. This approach boosts the body's ability to fight cancer while avoiding the severe side effects usually associated with systemic IL-12 therapy.

A mysterious disease called acute flaccid myelitis (AFM) has been appearing in emergency rooms for about a decade. The disease has caused otherwise healthy children to lose the ability to move their arms and legs, and some become completely paralyzed. AFM is caused by a virus that's a cousin of the polio virus, earning it the nickname "the new polio.” Journalist and physician Eli Cahan joins Host Flora Lichtman to explain what doctors have been observing, the research efforts toward developing a vaccine, and what this emerging disease reveals about our readiness for future outbreaks and pandemics.Read Cahan's article about what fighting this “new polio” might look like as our healthcare infrastructure gets dismantled.And, learning more about some non-cancerous cells may help researchers better understand how cancer progresses. When you think about how cancer spreads in the body, you're probably thinking about cancer cells—they divide uncontrollably, form into tumors, and hide from the immune system. So, it makes sense that studying the behavior of these cells is critical to our understanding of cancer. But now, researchers are looking more closely at the non-cancerous cells that co-exist within tumors and the surrounding tissues. They make up what's called the “colocateome.” Taking this more holistic approach to cancer research may help explain why some treatments don't work for all patients, and eventually may lead to more effective therapies. To better understand this expanding field, Host Ira Flatow talks with Sylvia Plevritis, a Stanford University cancer researcher. Guests:Dr. Eli Cahan is a journalist and physician based in Boston, Massachusetts.Dr. Sylvia Plevritis is a professor of biomedical data science and radiology at Stanford University.Transcript is available on sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

Support the show: http://www.newcountry963.com/hawkeyeinthemorningSee omnystudio.com/listener for privacy information.

»Jemand anderes musste sterben, damit meine Schwägerin leben kann.« Das sagte uns eine Freundin mit zitternder Stimme am Telefon. Ihre Schwägerin wurde wegen eines Tumors an der Niere behandelt. Ihr Zustand verschlechterte sich allerdings zusehends; Krankenhaus, Intensivstation, Koma. Die Ärzte hatten zunächst keine Erklärung für die Verschlechterung. Dann entdeckte einer von ihnen eine Infektion der Leber mit einem Herpesvirus. Die einzige Möglichkeit der Lebensrettung war eine Lebertransplantation. Erstaunlicherweise fand sich innerhalb von wenigen Tagen eine passende Leber, die dann transplantiert werden konnte. Unserer Freundin wurde klar, dass dies nur möglich war, weil ein anderer Mensch gestorben ist. Sie hatte damit einen Kernpunkt des Evangeliums wiedergegeben: Jesus Christus musste sterben, damit wir Menschen leben können.Grundsätzlich ist jeder Mensch durch die Sünde von Gott getrennt und steht unter dem Zorn Gottes. Aus unserer Kraft können wir diesen Zustand nicht ändern. Aber Jesus Christus, der Sohn Gottes, war nie getrennt von seinem Vater. Er war der Einzige, der völlig ohne Sünde und Schuld war, auch als er als Mensch auf dieser Erde lebte. Und deshalb konnte er unsere Sünde und alle Schuld auf sich nehmen und hat die Strafe dafür, den Tod, erduldet. Wer das für sich in Anspruch nimmt, für den ist die Trennung von Gott aufgehoben, weil seine Sünde gesühnt bzw. vergeben ist.Doch genauso, wie man sich keine Leber erarbeiten oder erkaufen kann, genauso wenig kann man sich diese Errettung erarbeiten oder kaufen. Sie ist ein Geschenk, das im Glauben angenommen werden muss. Dieses Angebot abzulehnen wäre fatal, denn das wäre tödlich und für ewig unveränderlich.Thomas KröckertskothenDiese und viele weitere Andachten online lesenWeitere Informationen zu »Leben ist mehr« erhalten Sie unter www.lebenistmehr.deAudioaufnahmen: Radio Segenswelle

Welcome to Season 2 of the Orthobullets Podcast.Today's show is Foundations, where we review foundational knowledge for frontline MSK providers such as junior orthopaedic residents, ER physicians, and primary care providers.This episode will cover the topic of⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Giant Cell Tumor, from our Pathology section at Orthobullets.com.Follow ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Orthobullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on Social Media:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Twitter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube

William Lowry, Ph.D., discusses manipulating metabolic pathways in hair follicle stem cells to inhibit tumorigenesis. By blocking glycolysis and glutamine lysis simultaneously, they observed tumor regression, highlighting the complex interplay between metabolism and cancer. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39256]

William Lowry, Ph.D., discusses manipulating metabolic pathways in hair follicle stem cells to inhibit tumorigenesis. By blocking glycolysis and glutamine lysis simultaneously, they observed tumor regression, highlighting the complex interplay between metabolism and cancer. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39256]

William Lowry, Ph.D., discusses manipulating metabolic pathways in hair follicle stem cells to inhibit tumorigenesis. By blocking glycolysis and glutamine lysis simultaneously, they observed tumor regression, highlighting the complex interplay between metabolism and cancer. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39256]

William Lowry, Ph.D., discusses manipulating metabolic pathways in hair follicle stem cells to inhibit tumorigenesis. By blocking glycolysis and glutamine lysis simultaneously, they observed tumor regression, highlighting the complex interplay between metabolism and cancer. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39256]

William Lowry, Ph.D., discusses manipulating metabolic pathways in hair follicle stem cells to inhibit tumorigenesis. By blocking glycolysis and glutamine lysis simultaneously, they observed tumor regression, highlighting the complex interplay between metabolism and cancer. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39256]

William Lowry, Ph.D., discusses manipulating metabolic pathways in hair follicle stem cells to inhibit tumorigenesis. By blocking glycolysis and glutamine lysis simultaneously, they observed tumor regression, highlighting the complex interplay between metabolism and cancer. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39256]

William Lowry, Ph.D., discusses manipulating metabolic pathways in hair follicle stem cells to inhibit tumorigenesis. By blocking glycolysis and glutamine lysis simultaneously, they observed tumor regression, highlighting the complex interplay between metabolism and cancer. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39256]

William Lowry, Ph.D., discusses manipulating metabolic pathways in hair follicle stem cells to inhibit tumorigenesis. By blocking glycolysis and glutamine lysis simultaneously, they observed tumor regression, highlighting the complex interplay between metabolism and cancer. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39256]

In this podcast episode of Integrative Cancer Solutions Dr. Karlfeldt interviews Dr. Chris Apfel about his integrative approaches to cancer treatment. Dr. Apfel shares his journey from traditional medicine to integrative oncology, sparked by his father's lung cancer diagnosis. This personal experience led him to question conventional cancer treatments after learning about their low success rates, particularly for stage four lung cancer. Dr. Apfel discusses his development of the Onca test, which can identify effective cancer therapies within a week by culturing tumor fragments. This test evaluates a wide range of treatments including chemotherapies, targeted therapies, and repurposed drugs. He emphasizes the importance of avoiding ineffective treatments that can harm the immune system and diminish quality of life, while highlighting the potential of repurposed drugs like statins, Metformin, and Itraconazole. The conversation addresses tumor heterogeneity and the need for representative biopsy samples, particularly from metastatic sites. Dr. Apfel explains that the Onca test is commercially available, with discounts offered to patients willing to share their data for research purposes. He discusses various methods for obtaining tumor samples and the importance of timing in the collection process.Dr. Apfel emphasizes patient advocacy and the need for patients to be informed about their treatment options. He notes that the Onca test can double the odds of a positive tumor response and significantly increase median survival rates. The podcast concludes with Dr. Apfel expressing interest in collaborating with Dr. Folt's center to help more cancer patients through this innovative approach to personalized cancer treatment.About Dr Chris Apfel:Chris Apfel, MD, PhD, MBA is a physician and clinical researcher with over 100 published papers, including a six-factor clinical prediction model published in NEJM that led to the development of The Apfel Score, a clinical calculator used universally to predict the risk of postoperative nausea and vomiting, and Dr Apfel's ultimate recruitment to the US and the University of California, San Francisco.Dr. Apfel was driven to revolutionize the field of cancer patient treatment after losing his mother to a long battle with ovarian cancer and his father to lung cancer. Witnessing their suffering inspired him leave the clinical department at UCSF to develop more efficient ways to identify the best treatment plans for cancer patients.Dr Apfel received his MD and PhD from the University of Giessen in Germany and his MBA from Wharton at the University of Pennsylvania. He is the founder and CEO of SageMedic.Dr. Apfel developed the Onca test, which can identify effective cancer therapies within a week by culturing tumor fragments, potentially doubling the odds of positive tumor response.Personal experience with his father's lung cancer led Dr. Apfel to question conventional treatments after discovering their low success rates for advanced cancers.The Onca test evaluates chemotherapies, targeted therapies, and repurposed drugs like statins and Metformin, which have shown promising results in cancer treatment.Tumor heterogeneity makes it crucial to obtain representative biopsy samples, particularly from metastatic sites, to avoid ineffective treatments.Patient advocacy is essential in cancer treatment, as patients need to make informed decisions about tissue handling before surgery and find oncologists willing to consider alternative treatments based on test results.----Grab my book A Better Way to Treat Cancer: A Comprehensive Guide to Understanding, Preventing and Most Effectively Treating Our Biggest Health Threat - https://www.amazon.com/dp/B0CM1KKD9X?ref_=pe_3052080_397514860 Unleashing 10X Power: A Revolutionary Approach to Conquering Cancerhttps://store.thekarlfeldtcenter.com/products/unleashing-10x-power-Price: $24.99-100% Off Discount Code: CANCERPODCAST1Healing Within: Unraveling the Emotional Roots of Cancerhttps://store.thekarlfeldtcenter.com/products/healing-within-Price: $24.99-100% Off Discount Code: CANCERPODCAST2----Integrative Cancer Solutions was created to instill hope and empowerment. Other people have been where you are right now and have already done the research for you. Listen to their stories and journeys and apply what they learned to achieve similar outcomes as they have, cancer remission and an even more fullness of life than before the diagnosis. Guests will discuss what therapies, supplements, and practitioners they relied on to beat cancer. Once diagnosed, time is of the essence. This podcast will dramatically reduce your learning curve as you search for your own solution to cancer. To learn more about the cutting-edge integrative cancer therapies Dr. Karlfeldt offer at his center, please visit www.TheKarlfeldtCenter.com

Am Lebensende tritt die Sprache als Kommunikationsmittel immer mehr in den Hintergrund. Durch Luftnot, Tumor oder fortschreitende Demenz sind Sterbende oft sprachlich eingeschränkt. Was dennoch bleibt sind nonverbale ´Kommunikationsversuche´, durch die Wünsche, Befinden, Vorlieben und Abneigungen mitgeteilt werden. Welche nonverbalen Kommunikationen es gibt und wie Du eine Beziehung ohne Worte aufbauen kannst, erfährst Du von Frau Dr. Steinmetz. Sie ist absolute Expertin auf dem Feld der ´Kommunikation ohne Worte´.  Shownotes: Gratis-Handbuch: 5 Handzeichen für die Pflege – Nonverbale Signale für mehr Verständnis im Pflegealltag: https://www.kommunikation-ohne-worte.de/5_handzeichen/ https://www.kommunikation-ohne-worte.de/ https://www.facebook.com/profile.php?id=100063848400811&ref=bookmarks https://www.youtube.com/channel/UCMax1AbHbcOxEdM0nUWse-A https://www.linkedin.com/in/dr-astrid-steinmetz-565236119/ Born to Pflege: Facebook: https://www.facebook.com/borntopflege/ Instagram: https://instagram.com/borntopflege/ YouTube: https://www.youtube.com/channel/UCITRHJ4qllFPZkXaPDrlq6A Homepage: https://borntopflege.de/

Today on Beating Cancer Daily, Saranne tackles the lighter side of living with Stage IV cancer by sharing one of her own humorous takes from her 31-day "Can We Laugh at Cancer" humor challenge. Drawing on her personal experience of 30 years beating Stage IV cancer and her journey as a single mom enduring treatment, Saranne highlights the challenges of chemo brain, especially in high-pressure situations like job interviews. Through laughter, reflection, and listener engagement, she encourages the community to adopt a comic perspective for resilience and stress relief. "It helps build your resiliency. It helps you when things are stressful and awful and yucky like they were for me..." ~SaranneToday on Beating Cancer Daily:·     Laughter is a powerful coping mechanism, even during cancer treatment.·     Chemo brain is a real and recognized side effect of chemotherapy.·     Humor can help build resilience and manage stress throughout the cancer journey.·     Job interviews while experiencing chemo brain can lead to funny and relatable moments.·     Saranne encourages listeners to contribute their own jokes or stories about cancer and chemo brain.·     The world has become more aware of chemo brain thanks to scientific research.·     Using humor can be a gentle way to acknowledge memory lapses during or after treatment. Ranked the Top 5 Best Cancer Podcasts by CancerCare News in 2024 & 2025, and #1 Rated Cancer Survivor Podcast by FeedSpot in 2024 Beating Cancer Daily is listened to in over 130 countries on 7 continents and has over 365 original daily episodes hosted by Stage IV survivor Saranne Rothberg!   To learn more about Host Saranne Rothberg and The ComedyCures Foundation:https://www.comedycures.org/ To write to Saranne or a guest:https://www.comedycures.org/contact-8 To record a message to Saranne or a guest:https://www.speakpipe.com/BCD_Comments_Suggestions To sign up for the free Health Builder Series live on Zoom with Saranne and Jacqui, go to The ComedyCures Foundation's homepage:https://www.comedycures.org/ Please support the creation of more original episodes of Beating Cancer Daily and other free ComedyCures Foundation programs with a tax-deductible contribution:http://bit.ly/ComedyCuresDonate THANK YOU! Please tell a friend whom we may help, and please support us with a beautiful review. Have a blessed day! Saranne   

Marlene ist gerade glücklich im 6. Monat schwanger, da erfährt sie: Sie hat einen aggressiven, meist tödlichen Hirntumor. Doch eine medizinische Studie macht ihr wieder Hoffnung.

Dr. John Sweetenham shares highlights from Day 2 of the 2025 ASCO Annual Meeting, including new data on the treatment of ER+/HER2-negative breast cancer and potentially practice-changing results for patients with cutaneous squamous cell carcinoma at high risk of recurrence.  Transcript Dr. John Sweetenham: Hello, I'm Dr. John Sweetenham, your host of the ASCO Daily News Podcast, welcoming you to our special coverage of the 2025 ASCO Annual Meeting. Today, I'll be bringing you my takeaways on selected abstracts from Day 2 of the Meeting. My disclosures are available in the transcript of this episode.  Today's selection features important, new data on the treatment of ER-positive, HER2-negative breast cancer, the use of tumor treating fields in combination with chemotherapy for locally advanced pancreatic cancer, and potentially practice-changing results for patients with cutaneous squamous cell carcinoma at high-risk of recurrence.  Our first selected abstract is LBA1000. This important phase 3 study was presented by Dr. Erika Hamilton from the Sarah Cannon Research Institute in Nashville and evaluated the use of a novel agent, vepdegestrant, in patients with ER-positive/HER2-negative breast cancer, which had progressed after first-line endocrine therapy. Vepdegestrant is a selective oral PROTAC estrogen receptor degrader, which targets wild-type and mutant estrogen receptor through a novel mechanism of action which directly harnesses the ubiquitin-proteasome system to degrade ER. It has potential advantages over fulvestrant, a selective ER degrader which has to be administered intramuscularly and has limited benefit in patients who progress after endocrine therapy plus a CDK4/6 inhibitor.  Building on the encouraging results from the initial phase 1/2 study of vepdegestrant, Dr. Hamilton reported results from the VERITAC-2 global phase 3 trial, comparing this agent with fulvestrant. The patients in the study had already received treatment with hormone therapy and a CDK inhibitor and were randomly assigned to receive treatment with either vepdegestrant (313 patients) or fulvestrant (311 patients). The vepdegestrant was taken orally each day, while the fulvestrant was given intramuscularly on days 1 and 15 of the first cycle of treatment and day 1 of each subsequent treatment cycle. Patients were stratified by the presence of wild-type ER or ESR1 mutation. A total of 43.3% of patients had ESR1 mutations; 136 of those were in the vepdegestrant group and 134 in the fulvestrant group.   For patients with ESR1 mutations, vepdegestrant significantly increased progression-free survival compared with fulvestrant. For patients who received vepdegestrant, the median PFS was 5 months versus 2.1 months for those who received fulvestrant. The clinical benefit rate was 42.1% in the vepdegestrant group vs. 20.2% in the fulvestrant group. The overall response rate was 18.6% in the vepdegestrant group compared with only 4% in the fulvestrant group.  The PFS and response benefits of vepdegestrant were largely restricted to the population with ESR1 mutations. Overall survival data are currently immature. The safety profile was favorable, with fewer than 5% of patients having dose reductions or discontinuation due to toxicity. The most frequent toxicities were fatigue, nausea, and elevated transaminases.  The authors concluded that oral vepdegestrant demonstrates statistically significant and clinically meaningful improvement in progression-free survival compared with fulvestrant in this group of patients with ESR1-mutated ER+/HER2- advanced breast cancer who have progressed after endocrine therapy and a CDK inhibitor. Patients with recurrent disease in this context are now routinely tested for ESR1 mutations, and this agent is for sure a potential treatment option for them.  The next study on today's episode, LBA4005, reports on the use of tumor treatment fields for patients with locally advanced pancreatic cancer. Tumor treatment fields are electric fields which disrupt cell division and may also induce an enhanced immune response, using a non-invasive portable device attached to the skin, and are already approved for the treatment of some cancers, including GBM and non-small cell lung cancer. A previous phase 2 trial, PANOVA-2, confirmed the feasibility and safety of using this approach in combination with gemcitabine plus or minus nabpaclitaxel in pancreatic cancer. In today's presentation, Dr. Vincent Picozzi from the Virginia Mason Medical Center in Seattle presented the results of the PANOVA-3 trial, a phase 3 study comparing gemcitabine and nabpaclitaxel with the same chemotherapy plus tumor treatment fields in patients with locally advanced pancreatic adenocarcinoma.  Five hundred and seventy-one eligible patients were enrolled in the study with a total of 405 (198 in the treatment field group and 207 in the standard arm) comprising the modified intent- to-treat population. The duration of chemotherapy treatment was comparable in both study arms, and patients receiving treatment fields had a median exposure of almost 27 weeks.  Statistically significant improvements were observed for several study endpoints, including overall survival (a median of 16.2 versus 14.2 months), distant PFS (at 13.9 versus 11.5 months) and pain-free survival (at 15.2 versus 9.1 months), all in favor of the treatment fields arm. Although quality of life data were not reported in detail, the authors noted a significant improvement in global health status in the treatment fields arm. Safety data showed a higher level of skin adverse events in the treatment fields arm but were otherwise as expected for the GnP combination.  These are quite remarkable results which add to the growing evidence base for tumor treatment fields and are particularly compelling in this patient group given the substantial improvement in pain-free survival. It will be especially interesting to see the mature analysis of the quality-of-life endpoints in a subsequent report.  The final selection today is Abstract 6001, which describes the C-POST trial, a phase 3 trial of adjuvant cemiplimab versus placebo in patients with high-risk cutaneous squamous cell carcinoma of the skin. This study was presented by Dr. Danny Rischin from the Peter MacCallum Cancer Centre in Melbourne, Australia.   Although surgical resection with or without adjuvant radiation is curative in 90% of patients with cutaneous squamous cell carcinoma, high-risk features, including nodal disease, skin and subcutaneous metastases, perineural invasion and bone involvement, predict for an inferior prognosis.  Cemiplimab, a PD-1 targeting antibody is standard therapy for patients with locally advanced or metastatic disease who are not candidates for curative surgical resection or radiation therapy, with an overall response rate of almost 50%.  The C-POST study evaluated the use of cemiplimab as adjuvant therapy following surgery and radiation in high-risk patients, compared with placebo. Treatment was administered at 3-week intervals for 12 weeks, and then 6-week intervals for a further 36 weeks, with a primary endpoint of disease-free survival. Four hundred and fifteen patients were randomized in the study, 209 to cemiplimab and 206 to placebo. With median follow-up at 24 months, Dr. Rischin reported a highly significant improvement in disease-free survival for the cemiplimab arm, 49.4 months for placebo versus not reached for cemiplimab, with improvements also observed in the rates of locoregional recurrence and distant recurrence at 80% and 60% reductions, respectively. No new safety signals were observed.  This study is potentially practice-changing and provides strong evidence that cemiplimab should be considered the new standard of care in this clinical context.  Thanks for listening today and join me again tomorrow to hear more top takeaways from ASCO25. If you value the insights that you hear on the ASCO Daily News Podcast, please remember to rate, review, and subscribe wherever you get your podcasts.  Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speaker:   Dr. John Sweetenham   Follow ASCO on social media:    @ASCO on Twitter   @ASCO on Bluesky   ASCO on Facebook   ASCO on LinkedIn    Disclosures:   Dr. John Sweetenham:   No relationships to disclose  

Click to Subscribe: https://bit.ly/Youtube-Subscribe-SoapDirt Bold and the Beautiful spoilers for June 2-6, 2025 see Luna Nozawa (Lisa Yamada) will be at the center of the chaos with her lustful advances towards Will Spencer (Crew Morrow) and a possible murder plot. Liam Spencer's (Scott Clifton) health takes a concerning turn on the CBS soap opera.  B&B spoilers see Hope Logan (Annika Noelle) shockingly accepts Carter Walton's (Lawrence Saint-Victor) proposal. The news of their engagement will soon reach Brooke Logan (Katherine Kelly Lang), who is ecstatic and immediately starts planning a celebration. Ridge Forrester (Thorsten Kaye) and Steffy Forrester (Jacqueline MacInnes Wood) express reservations about Hope and Carter's sudden reunion.  Spoilers for Bold and Beautiful see Luna continues her pursuit of Will, which escalates to a full-blown brawl with Electra Forrester (Laneya Grace). This might signal Lisa Yamada's temporary exit from the show. Sheila Carter (Kimberlin Brown) warns Luna against making past mistakes and even suggests Luna leave town. Sheila's concern for her granddaughter's actions heightens as Luna suggests eliminating Steffy, which Sheila does not agree with. Hope and Carter plan their wedding, while Brooke struggles with Ridge's absence in her life the week of 6/2 - 6/6/2025.   Visit our Bold and the Beautiful section of Soap Dirt: https://soapdirt.com/category/bold-and-the-beautiful/ Listen to our Podcasts: https://soapdirt.podbean.com/ Check out our always up-to-date Bold and the Beautiful Spoilers page at: https://soapdirt.com/bold-and-the-beautiful-spoilers/ Check Out our Social Media... Twitter: https://twitter.com/SoapDirtTV Facebook: https://www.facebook.com/SoapDirt Pinterest: https://www.pinterest.com/soapdirt/ TikTok: https://www.tiktok.com/@soapdirt Instagram: https://www.instagram.com/soapdirt/

In this podcast episode, host Ruchika Talwar, MD, is joined by Amin Mazloom, PhD, Senior Vice President of Bioinformatics, Biostatistics & Data Innovation, and Janine LoBello, DO, Senior Clinical Laboratory Medical Director at Exact Sciences to discuss patient-matched tumor-normal (PMTN) sequencing and why it matters for oncologists. Drs. Mazloom and LoBello discuss PMTN sequencing as a gold standard method for calculating tumor mutational burden and personalized therapy selection and share their thoughts on the future of cancer testing.

In this podcast episode, host Ruchika Talwar, MD, is joined by Amin Mazloom, PhD, Senior Vice President of Bioinformatics, Biostatistics & Data Innovation, and Janine LoBello, DO, Senior Clinical Laboratory Medical Director at Exact Sciences to discuss patient-matched tumor-normal (PMTN) sequencing and why it matters for oncologists. Drs. Mazloom and LoBello discuss PMTN sequencing as a gold standard method for calculating tumor mutational burden and personalized therapy selection and share their thoughts on the future of cancer testing.

In today's episode, Saranne, the founder of the Comedy Cures Foundation, shares her unique perspective on humor and cancer treatment. She introduces the "Tumor Humor" concept and how she developed her comic perspective while undergoing cancer treatment. Saranne shares a humorous joke about her blood test results and explains the inspiration behind it. She encourages listeners to find the comedic elements in their own cancer journey and invites them to share their jokes or stories with the Comedy Cures Foundation. Join Saranne as she explores the intersection of laughter and healing in the face of cancer.Ranked the Top 5 Best Cancer Podcasts by CancerCare News in 2024 & 2025, and #1 Rated Cancer Survivor Podcast by FeedSpot in 2024 Beating Cancer Daily is listened to in over 130 countries on 7 continents and has over 365 original daily episodes hosted by Stage IV survivor Saranne Rothberg!   To learn more about Host Saranne Rothberg and The ComedyCures Foundation:https://www.comedycures.org/ To write to Saranne or a guest:https://www.comedycures.org/contact-8 To record a message to Saranne or a guest:https://www.speakpipe.com/BCD_Comments_Suggestions To sign up for the free Health Builder Series live on Zoom with Saranne and Jacqui, go to The ComedyCures Foundation's homepage:https://www.comedycures.org/ Please support the creation of more original episodes of Beating Cancer Daily and other free ComedyCures Foundation programs with a tax-deductible contribution:http://bit.ly/ComedyCuresDonate THANK YOU! Please tell a friend whom we may help, and please support us with a beautiful review. Have a blessed day! Saranne 

¿Vds se acuerdan de en qué pensaban cuando volvieron de una anestesia? Hay gente que regresa a la consciencia diciendo palabrotas, insultando, o con una enorme felicidad, o llorando, o destapando verdades y secretos, que también se ha dado el caso.Hace un año Sergio volvió del quirófano pensando en flores.Sergio Ruiz es Policía Nacional y ha trabajado la mayor parte de su carrera como guía canino en Zaragoza. Hace un año se le diagnosticó un tumor cerebral y, al volver a vestirse con el uniforme, se quiso pasar a dar las gracias por el Miguel Servet a todo el personal sanitario que estuvo a su lado.Vio flores al ir volviendo de la anestesia.Sergio ha ido al Hospital con un puñado de ellas, cada una en su maceta, para todos los profesionales sanitarios que le atendieron aquellos días en los que ni él mismo sabía bien qué le estaba pasando.Las flores en el subconsciente de Sergio ya están en las manos de los que han permitido que vuelva a sentirse ...

In this episode, Dr. Ruchika Talwar, a urologic oncologist at Vanderbilt University Medical Center, Dr. Adham Jurdi, a medical oncologist and Senior Director of Oncology at Natera, delve into the groundbreaking world of tumor-informed molecular residual disease testing. Discover how circulating tumor DNA (ctDNA) is revolutionizing cancer detection and treatment, providing real-time insights that surpass traditional imaging methods. Learn about the decades-long journey to perfect this technology, its clinical implications, and the exciting advancements on the horizon.

Johann Ilgenfritz's life changed in 2011 when he had a heart attack and six months later was diagnosed with cancer. After unsuccessful Radio Therapy he researched for a cure, soon realizing that that there was no central point for reliable online health information. He decided to create a platform and launched UK Health Radio, while still fighting cancer. After overcoming cancer through nutritional and lifestyle changes, he earned the title "The Curator of Health Expertise" from the press. His guiding principle is simple: "Good health is a choice." Initially, he saw cancer as the root of his illness but later realized it was merely a symptom of an already unwell body. He understood that by addressing the underlying cause, he could transform the outcome. With this vision, UK Health Radio (https://ukhealthradio.com/) has embraced a clear mission: to inspire and empower people to take responsibility for their own health. This does not mean taking your health into your own hands, but to be part of the process of attaining and/or keeping your health freedom. It is all about being informed, being empowered, taking action and being healthy! UK Health Radio delivers information through 41 shows airing 24/7, reaching over 1.5 million very dedicated listeners and is now also available on 11 podcast platforms worldwide. In February of 2024, Johann created The Alkaline Collective Mastermind (https://alkaline-collective.com/), a dedicated online community for those battling cancer, aiming to prevent it, or striving to stop it's recurrence. Designed for individuals who are committed to hold themselves accountable, and seek a comprehensive toolbox of resources.

In this episode, we review the high-yield topic of⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Islet Cell Tumors from the Gastrointestinal section.Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets

In this episode of the Hand Surgery Resource Podcast, Dr. Larry Hurst shares more about Giant Cell Tumor of the Tendon Sheath, more popularly known as Xanthoma.A giant cell tumor of the tendon sheath (GCTTS) is a slow growing, usually painless benign lesion localized at the extremities. It is the second most common benign tumor of the hand after ganglion cyst.Find out more about it here: https://www.handsurgeryresource.net/xanthoma

Biden's malignant metastatic tumor must be given everything it needs to defend itself from unprovoked attacks by radical oncologists. Reading by Tim Foley.

INE aprueba estrategia en caso de empate en elecciones del Poder JudicialEn Chihuahua extirpan tumor de más de dos kilogramos a mujer embarazadaLa única manera de avanzar en la paz es un diálogo entre Trump y Putin: Marco Rubio Más información en nuestro Podcast

Send us a textIn this Journal of Vascular and Interventional Radiology (JVIR) audio episode, JVIR blog Editor Peter Li, MD, MS, uses artificial intelligence (AI) platform ElevenLabs to produce a podcast discussion on the November 2024 JVIR paper, "Using Voxel-Based Dosimetry to Evaluate Sphere Concentration and Tumor Dose in Hepatocellular Carcinoma Treated with Yttrium-90 Radiation Segmentectomy with Glass Microspheres."Related resources:Read the original articleRead the blog entry, "Vox Voxel: Calculating Y90 Tumor Dose and Sphere Distribution with Voxel Dosimetry"SIR thanks BD for its generous support of the Kinked Wire.Contact us with your ideas and questions, or read more about about interventional radiology in IR Quarterly magazine or SIR's Patient Center.(c) Society of Interventional Radiology.Support the show

Kathleen investigates reports that methylene blue may shrink cancerous tumours. Peter talks about future guests and our featured author. Kathleen's Deep Dive Kathleen discusses a report from Dr. Mercola which explores the anticancer properties of Methylene Blue, a synthetic compound traditionally used as a dye and in medical treatments. It highlights research indicating that Methylene Blue may have the potential to target cancer cells through mechanisms such as inducing apoptosis and inhibiting tumour growth. The article likely reviews studies and clinical findings to evaluate its efficacy and safety as an adjunct or alternative cancer therapy. It aims to inform readers about the current scientific understanding and future research directions regarding Methylene Blue's role in oncology. The article is at the link in the "mentioned On The Show" section below. This Week's Health Tip  Kathleen spoke about Dr. Morse's Ultimate Detox Kit and following a diet of raw fruit and vegetables. She explains the transformative power of the Ultimate Detox Kit and fasting program as it guides your body's natural detoxification process to unclog all channels of elimination, flush toxins from the system, and revitalize the body's organ systems and functions. The Ultimate Detox is a 16-week program that includes 9 rotating detoxification formulas, with fasting and lifestyle recommendations. Health Declassified is brought to you by Peter Wright & Kathleen Beauvais contact us to be a guest on our show. https://HealthDeclassified.com  peter@healthdeclassified.com    kathleen@healthdeclassified.com  Get our weekly newsletter for news of future guests. Subscribe here   Our Affiliate Suppliers Dr. Morse's Herbal Health Club Remedies https://bit.ly/3Oc2J8L Science Driven Supplements - Circuguard & OxyBoost https://bit.ly/3VPzsV8 MyWayCBD https://bit.ly/4jFzmd0 BAM Metrics Exercise Equipment https://bit.ly/3SMnZom B3 Sciences BFR bands  https://bit.ly/4g9HmzV Chatterboss Virtual Assistants https://bit.ly/3Obmzlb   Follow us on social media Spotify                        https://open.spotify.com/show/1N3yM4lUuBYGMByhwuUDVy Facebook Group        https://www.facebook.com/groups/480434235068451 FaceBook Page                https://www.facebook.com/HealthDeclassified Twitter        X                https://x.com/HealthDeclass Instagram                https://www.instagram.com/healthdeclassified/   Here are some of the tools we use to produce this podcast. Kit for sending emails and caring for subscribers Hostgator for website hosting. Podbean for podcast hosting Airtable for organizing our guest bookings and automations.   Clicking on some links on this site will let you buy products and services which may result in us receiving a commission, however, it will not affect the price you pay.    

In dieser Folge ist Ingwar Perowanowitsch zu Gast. Er ist Politikwissenschaftler, freier Journalist und leidenschaftlicher Radreisender. Wir reden über sogenannte "Donauschwaben", Politisierung durch Radeln und warum Deutschland sich so schwertut, fahrrad- und umweltgerechtere Städte zu planen. Über sein Gefühl der Bonus-Lebenszeit, überemotionale Männer mit starken Auto-Biografien und was ihm beim Radfahren durch muslimische Länder aufgefallen ist. Ingwars Film "Mit dem FAHRRAD nach ASERBAIDSCHAN 4K" https://www.youtube.com/watch?v=N9ImVqRloWs (03:20) Passkontrolle (09:25) Klischee-Check (25:45) Analoges Aufwachsen, Durchmogeln & Entführt im Sommer (45:40) Tumor im Knie: "Ich bin jeden Tag dankbar" (55:20) Politisierung durch Radwege, Auto-Biografie & Revolution der Städte (1:34:05) Radreise nach Baku: Reiseprivilegien & Gespräche über Gott und die Welt "OUT OF TIBET" PODCAST von Namri Dagyab https://open.spotify.com/show/3qpuT338hjIvOTWbAhq0cv?si=aaff318936b04699 CIVIS-MEDIENPREIS LIVE: https://www.civismedia.eu/medienpreis/medienpreis-2025/livestream/ SUPPORT: Halbe Katoffl unterstützen: https://halbekatoffl.de/unterstuetzen/ Paypal: frank@halbekatoffl.de Steady: https://steadyhq.com/de/halbekatoffl/about Überweisung/ Dauerauftrag: Schreib an frank@halbekatoffl.de | Stichwort: KONTO

Got Health Questions or Comments?

Today on Beating Cancer Daily, Saranne brings a light-hearted and uplifting perspective to the challenging journey of cancer patients by sharing her innovative approach to humor through her experience with Stage IV cancer. From being a patient herself to founding the Comedy Cures Foundation, Saranne provides a unique narrative filled with tumor humor, specifically focusing on the often arduous but necessary cancer scans. Saranne recounts a personal, humorous anecdote about confusing airport security scans with medical scans, offering listeners a chance to laugh and view their own cancer experiences from a comic perspective.Ranked the Top 5 Best Cancer Podcasts by CancerCare News in 2024 & 2025, and #1 Rated Cancer Survivor Podcast by FeedSpot in 2024 Beating Cancer Daily is listened to in over 130 countries on 7 continents and has over 365 original daily episodes hosted by Stage IV survivor Saranne Rothberg!   To learn more about Host Saranne Rothberg and The ComedyCures Foundation:https://www.comedycures.org/ To write to Saranne or a guest:https://www.comedycures.org/contact-8 To record a message to Saranne or a guest:https://www.speakpipe.com/BCD_Comments_Suggestions To sign up for the free Health Builder Series live on Zoom with Saranne and Jacqui, go to The ComedyCures Foundation's homepage:https://www.comedycures.org/ Please support the creation of more original episodes of Beating Cancer Daily and other free ComedyCures Foundation programs with a tax-deductible contribution:http://bit.ly/ComedyCuresDonate THANK YOU! Please tell a friend whom we may help, and please support us with a beautiful review. Have a blessed day! Saranne 

El líder del Caucus Hispano y otros dos congresistas visitaron a la familia en México; Espaillat detalla cómo buscan ayudar a la niña enferma y a sus padres.

BUFFALO, NY - May 9, 2025 – A new #research paper was #published in Oncotarget, Volume 16, on May 8, 2025, titled “METTL3 promotes oral squamous cell carcinoma by regulating miR-146a-5p/SMAD4 axis." In this study, researchers Jayasree Peroth Jayaprakash, Pragati Karemore, and Piyush Khandelia from the Birla Institute of Technology and Science, India, discovered that a molecule called METTL3 contributes to the development and spread of oral squamous cell carcinoma (OSCC). The study shows that METTL3 increases the levels of a small RNA molecule called miR-146a-5p, which blocks SMAD4, a key tumor-suppressing gene. These findings help explain why oral cancers are difficult to treat and may offer a new target for more effective therapies. Oral squamous cell carcinoma is a common and aggressive cancer affecting the mouth and throat. It has a high death rate, mainly due to late detection, treatment resistance, and the cancer's ability to invade nearby tissues. In this study, the researchers focused on METTL3, an enzyme that adds chemical tags known as m6A marks to RNA, which change how genetic information is used by cells. They found that METTL3 is unusually active in OSCC cells, causing an increase in miR-146a-5p. This molecule, in turn, blocks the function of SMAD4, which helps control how cells grow and die in our bodies. “METTL3, the primary m6A RNA methyltransferase, is significantly upregulated in OSCC cells leading to increased global m6A levels.” When METTL3 was reduced or chemically blocked, miR-146a-5p levels dropped and SMAD4 levels increased. This shift slowed the growth of cancer cells, increased their death, and made them less likely to spread. When researchers reintroduced miR-146a-5p or lowered SMAD4 levels again, the cancer-promoting behavior returned. These results show that the METTL3–miR-146a-5p–SMAD4 pathway plays a key role in OSCC. The findings open up new possibilities for treatment. Drugs that block METTL3 or miR-146a-5p or that restore SMAD4 could slow or stop tumor growth. One such drug, STM2457, which targets METTL3, has already shown promise in lab studies. As research progresses, targeting this molecular pathway may offer a new strategy in treating OSCC. This discovery improves our understanding of how OSCC develops and avoids the body's defenses. By interfering with this newly discovered pathway, future treatments may become more successful, improving survival rates and quality of life for people with this disease. DOI - https://doi.org/10.18632/oncotarget.28717 Correspondence to - Piyush Khandelia - piyush.khandelia@hyderabad.bits-pilani.ac.in Video short - https://www.youtube.com/watch?v=o5XuDlcIma8 Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28717 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Support the show and get 50% off MCT oil with free shipping – leave us a review on iTunes and let us know!Ever notice how quickly conventional oncology jumps straight to chemo, radiation, or the scalpel—and how rarely anyone asks why that tumor showed up in the first place?In this episode, I sit down with Dr. Michael Karlfeldt, naturopathic physician and author of the Amazon bestseller A Better Way to Treat Cancer. Michael has treated 100,000‑plus patients since 1987 and hosts Integrative Cancer Solutions and Integrative Lyme Solutions podcasts. His message is simple: cancer is less a genetic death sentence and more of a whole‑body systems failure which we can reverse, once we fix inflammation, mitochondrial dysfunction, mindset, and (yes) the gut.Michael shares the real root causes of cancer that no one is talking about. He reveals how cancer cells hijack our natural energy-producing pathways, why detecting a tumor is just the tip of the iceberg, and how to create an environment where cancer cells simply can't survive.Whether you're currently battling cancer or on a healing journey, or you are fortunate to have a clean bill of health, this episode will arm you with the tools to kick cancer to the curb for good. Let's dive in.“I don't think that it (cancer) is a genetic disorder. I think genetics is something that is kind of secondary. I believe that it is that shift in how the cell produces energy." ~ Dr. Michael Karlfeldt About Dr. Michael KarlfeldtDr. Michael Karlfeldt is a board-certified naturopathic doctor and the founder of the Karlfeldt Center in Boise, Idaho. He specializes in integrative oncology and has treated over 100,000 patients across 30+ years. He's the author of A Better Way to Treat Cancer, host of the Integrative Cancer Solutions and Integrative Lyme Solutions podcasts, and an expert in therapies like IV Vitamin C, photodynamic therapy, frequency medicine, and personalized peptide immunotherapy.Connect with Dr. Karlfeldt- Website: https://thekarlfeldtcenter.com/ - Book: The Better Way to Treat Cancer: https://a.co/d/8RjXQ8C - YouTube: https://www.youtube.com/@KarlfeldtCenter - Phone: (208) 338-8902Connect with Chris Burres:- Website: https://www.myvitalc.com/ - Website: http://www.livebeyondthenorms.com/ - Instagram: https://www.instagram.com/chrisburres/ - TikTok: https://www.tiktok.com/@myvitalc - LinkedIn: https://www.linkedin.com/in/chrisburres/

In this radiology lecture, we review the ultrasound appearance of giant cell tumor of the tendon sheath! Key teaching points The post Ultrasound of Giant Cell Tumor of the Tendon Sheath appeared first on Radquarters.

Show #2405 Show Notes: Luke 8: https://www.biblegateway.com/passage/?search=Luke%208&version=KJV ‘Manifest’: https://webstersdictionary1828.com/Dictionary/manifest LAN Events: https://thelibertyactionnetwork.com/calendar/ Mathematics of the Mound Builders: https://www.youtube.com/watch?v=NZDYuo2bGrM Parasites in Tumor: https://www.facebook.com/reel/919497673449737 Cancer-Fighting benefits of Ivermectin: https://choiceclips.whatfinger.com/2025/05/07/the-remarkable-cancer-fighting-benefits-of-ivermectin-ivermectin-can-actually-kill-cancer-stem-cells-which-are-often-resistant-to-chemotherapy/ New Cancer Treatment Protocol: https://www.thegatewaypundit.com/2024/10/new-cancer-treatment-protocol-featuring-horse-dewormer-ivermectin/ Government Admits it knew covid […]

[include file=get-in-itunes.html] It was nice to have my partner in crime back! Today we had another Free For All Friday show which was a lot of fun. We had our first caller call in and that was a lot of fun also. Stella from New York shared some of her experiences with different things she’s […] The post Updates On Kate’s Silent Retreat, Tumors Coming Out During Coffee Enemas, Inspirational Information, Listeners Call In & More! appeared first on Extreme Health Radio.

Dr. Jason Williams, President and Director of Interventional Oncology and Immunotherapy at the Williams Cancer Institute, uses a combination of Pulse Electric Field technology to ablate tumors and direct injection of immunotherapy drugs into the tumor to stimulate the immune system. This approach can be used in conjunction with traditional cancer treatments and has fewer side effects than standard immunotherapy. This method is part of the broader trend in cancer research to provide a more targeted approach to treating tumors. Jason explains, "Our big focus is going to the tumor itself, so we do treatments directly at the tumor, and we do a combination of things. We do things that will be considered ablation where we're using different technologies or energies — I'll explain — particularly, we use one called Pulse Electric Field (PEF), which kills the tumor by essentially shocking it, and that kills it in a way that actually makes the immune system see it better. You're not trying to kill all of the tumor, you're trying to kill pieces for the immune system. Then we inject drugs into that area of the tumor, particularly immunotherapy drugs, but it can be other drugs as well, and just really taking the fight to the cancer right in the tumor." "I think that our mistake in cancer treatments is that we're not addressing the tumors directly. I mean, it's one thing to expect that you're going to take a drug orally or intravenously and that it's going to arrive and make it to the cancer cells. Still, the other way is to go right into it, putting the drugs there, and particularly with immunotherapies, where you want to attract the immune system to it. You want those drugs in the cancer, you don't want them just everywhere in the body." #WilliamsCancer #Cancer #Oncology #Tumors #Immunotherapy #PulseElectricField #ImmuneSystem #TargetingTumors WilliamsCancerInstitute.com Download the transcript here

Dr. Jason Williams, President and Director of Interventional Oncology and Immunotherapy at the Williams Cancer Institute, uses a combination of Pulse Electric Field technology to ablate tumors and direct injection of immunotherapy drugs into the tumor to stimulate the immune system. This approach can be used in conjunction with traditional cancer treatments and has fewer side effects than standard immunotherapy. This method is part of the broader trend in cancer research to provide a more targeted approach to treating tumors. Jason explains, "Our big focus is going to the tumor itself, so we do treatments directly at the tumor, and we do a combination of things. We do things that will be considered ablation where we're using different technologies or energies — I'll explain — particularly, we use one called Pulse Electric Field (PEF), which kills the tumor by essentially shocking it, and that kills it in a way that actually makes the immune system see it better. You're not trying to kill all of the tumor, you're trying to kill pieces for the immune system. Then we inject drugs into that area of the tumor, particularly immunotherapy drugs, but it can be other drugs as well, and just really taking the fight to the cancer right in the tumor." "I think that our mistake in cancer treatments is that we're not addressing the tumors directly. I mean, it's one thing to expect that you're going to take a drug orally or intravenously and that it's going to arrive and make it to the cancer cells. Still, the other way is to go right into it, putting the drugs there, and particularly with immunotherapies, where you want to attract the immune system to it. You want those drugs in the cancer, you don't want them just everywhere in the body." #WilliamsCancer #Cancer #Oncology #Tumors #Immunotherapy #PulseElectricField #ImmuneSystem #TargetingTumors WilliamsCancerInstitute.com Listen to the podcast here

This episode summarizes recent updates on: Tumor infiltrating clonal hematopoiesis (TI-CH) and its apparent negative impact on solid tumors (https://www.nejm.org/doi/full/10.1056/NEJMoa2413361) Updated dostarlimab data on MMRd use in rectal cancer and other solid tumors in the neoadjuvant (definitive?!?!) setting (https://www.nejm.org/doi/full/10.1056/NEJMoa2404512) Phase 1 study of 7 + 3 + Venetoclax (https://doi.org/10.1182/blood.2024026700) Zongertinib, a new HER2 TKI (https://www.nejm.org/doi/full/10.1056/NEJMoa2503704)

You'll have no Kimchi, no horseradish and no Lt. Yar! Copycat Dipshitter. Tumor fruit. Port a Potty Perks. Shriracha Schmear. Gotta Go At Costco. Ass Cheek to Ass Cheek. I Dream Of GKneeeeeeeeeeeeeeeeeeeeeeeeeeeee! Neither a Miracle, Nor a Whip. Runner butt poo. Friendly Wackadoo. Non-Organic Dipshits. The darker the berry the hotter it is. John Wayne's Sperm. Tech Time with Mr. Las Vegas Tom Merritt. Alicia Stockholm Recommentals with Randy and Nicole and more on this episode of The Morning Stream. Hosted on Acast. See acast.com/privacy for more information.

You'll have no Kimchi, no horseradish and no Lt. Yar! Copycat Dipshitter. Tumor fruit. Port a Potty Perks. Shriracha Schmear. Gotta Go At Costco. Ass Cheek to Ass Cheek. I Dream Of GKneeeeeeeeeeeeeeeeeeeeeeeeeeeee! Neither a Miracle, Nor a Whip. Runner butt poo. Friendly Wackadoo. Non-Organic Dipshits. The darker the berry the hotter it is. John Wayne's Sperm. Tech Time with Mr. Las Vegas Tom Merritt. Alicia Stockholm Recommentals with Randy and Nicole and more on this episode of The Morning Stream. Hosted on Acast. See acast.com/privacy for more information.

Lona Twins Talk All: Twin Sisters, Learning Disability, Mental Health, Tumor, CHISME & MORE!! Thanks to my sponsors: Find exactly what you're booking for on https://Booking.com, Booking.YEAH! • Don't forget to subscribe to the podcast for free wherever you're listening or by using this link: https://bit.ly/NochedePendejadasPodcast • If you like the show, telling a friend about it would be helpful! You can text, email, Tweet, or send this link to a friend: https://bit.ly/NochedePendejadasPodcast Follow Alannized on IG Follow Alannized on TikTok Follow Alannized on Twitter  Learn more about your ad choices. Visit podcastchoices.com/adchoices